Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › capmatinib

capmatinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of capmatinib

4 trials tracked of capmatinib.

4Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 4
  1. Phase 2 Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC Completed
  2. Phase 2 Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) Completed
  3. Phase 2 Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer Completed
  4. Phase 2 Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report reviews capmatinib off-label use in two patients with radiation-induced MET-fusion glioma
Oncology Sys. Review
Case report reviews capmatinib off-label use in two patients with radiation-induced MET-fusion glioma Capmatinib Shows Promise Against Rare Brain Tumors
This case report with literature review describes off-label capmatinib use in two patients with radiation-induced gliomas harboring MET fusi…
A drug used for lung cancer is now helping some children with rare, deadly brain tumors live longer, even when standard treatments fail.
Frontiers Apr 28, 2026
Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations
Pulmonology & Critical Care Phase II
Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations Could a targeted pill help Chinese patients with a specific lung cancer mutation?
An open-label, multicenter phase II study evaluated capmatinib in 36 Chinese adult patients with advanced NSCLC harboring MET exon 14 skippi…
A targeted pill shrank tumors in Chinese lung cancer patients with a specific MET gene mutation, offering a new treatment option for this ge…
CT.gov Mar 30, 2026